COVID-19 mild to moderate | |
COVID-19 mild to moderate | |
janus kinase (JAK) inhibitor | |
tofacitinib | Murugesan |
6141 | Rodriguez-Garcia, 2020 | 1 | 10 | 0 | not a RCT | risk of bias not avaialble | |
6415 | Cantini, 2020 | 2 | 31 | 0 | excluded | not a RCT | risk of bias not avaialble |
6430 | Cantini, 2020 | 1 | 13 | 4 | not a RCT | high risk of bias |